Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Lack of enzyme causes ALS says Italian study

Lack of enzyme causes ALS says Italian study

Breakthrough spurs hope for new therapy of terminal illness

ROME, 12 January 2022, 12:45

Redazione ANSA

ANSACheck

- ALL RIGHTS RESERVED

-     ALL RIGHTS RESERVED
- ALL RIGHTS RESERVED

The lack of an enzyme in the body causes the fatal nerve-wasting disease Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig's Disease, an Italian study has shown, raising hope for new treatment options.
    The study by Milan's Mario Negri Institute and Turin's Città della Salute, published in the journal Brain, shows that the lack of cyclophillin A induces the terminal condition, which is also known as Motor Neuron(e) Disease (MND).
    Conducted in animal models and on humans, the breakthrough "could be a first important step towards developing a therapy," said the researchers.
    ALS is a neurodegenerative disease that results in the progressive loss of motor neurons that control voluntary muscles.
    The affected muscles are responsible for chewing food, speaking, and walking.
    Motor neuron loss continues until the ability to eat, speak, move, and finally the ability to breathe is lost.
    ALS eventually causes paralysis and early death, usually from respiratory failure.
    There is no known cure for ALS, and the goal of treatment is to improve symptoms.
    The disease became well known in the United States in the 20th century when in 1939 it affected baseball player Lou Gehrig and later worldwide following the 1963 diagnosis of cosmologist Stephen Hawking.
    The average survival from onset to death is two to four years, though this can vary, and about 10% survive longer than 10 years.
    In Europe, the disease affects about two to three people per 100,000 per year.
    It hits professional soccer players on average two times more than the general population and Serie A players are hit six times more, a study from Milan's Mario Negri Institute said in 2019.
    There have been several high-profile cases in Italy of right-to-die ALS sufferers committing suicide due to the hopelessness and physical incapacitation of the condition.
   
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Share

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.